136 related articles for article (PubMed ID: 37902953)
1. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress.
Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
Expert Opin Investig Drugs; 2023; 32(11):971-983. PubMed ID: 37902953
[TBL] [Abstract][Full Text] [Related]
2. B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.
Cremer J; Elston R; Campbell FM; Kendrick S; Paff M; Quinn G; Theodore D
Adv Ther; 2023 Sep; 40(9):4101-4110. PubMed ID: 37393402
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
Yuen MF; Lim SG; Plesniak R; Tsuji K; Janssen HLA; Pojoga C; Gadano A; Popescu CP; Stepanova T; Asselah T; Diaconescu G; Yim HJ; Heo J; Janczewska E; Wong A; Idriz N; Imamura M; Rizzardini G; Takaguchi K; Andreone P; Arbune M; Hou J; Park SJ; Vata A; Cremer J; Elston R; Lukić T; Quinn G; Maynard L; Kendrick S; Plein H; Campbell F; Paff M; Theodore D;
N Engl J Med; 2022 Nov; 387(21):1957-1968. PubMed ID: 36346079
[TBL] [Abstract][Full Text] [Related]
5. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
[TBL] [Abstract][Full Text] [Related]
6. [Antisense oligodeoxynucleotides: the certain but limited efficacy and the uncovering mechanisms for the cure of chronic hepatitis B].
Li DY; Lu DJ; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):192-197. PubMed ID: 37137837
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses.
Han K; Theodore D; McMullen G; Swayze E; McCaleb M; Billioud G; Wieland S; Hood S; Paff M; Bennett CF; Kwoh TJ
Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1191-1202. PubMed ID: 35971951
[TBL] [Abstract][Full Text] [Related]
8. RNA interference as a novel treatment strategy for chronic hepatitis B infection.
Hui RW; Mak LY; Seto WK; Yuen MF
Clin Mol Hepatol; 2022 Jul; 28(3):408-424. PubMed ID: 35172540
[TBL] [Abstract][Full Text] [Related]
9. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
10. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
[TBL] [Abstract][Full Text] [Related]
11. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.
Hui RW; Mak LY; Seto WK; Yuen MF
Expert Opin Emerg Drugs; 2022 Jun; 27(2):127-140. PubMed ID: 35511483
[TBL] [Abstract][Full Text] [Related]
12. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
Billioud G; Kruse RL; Carrillo M; Whitten-Bauer C; Gao D; Kim A; Chen L; McCaleb ML; Crosby JR; Hamatake R; Hong Z; Garaigorta U; Swayze E; Bissig KD; Wieland S
J Hepatol; 2016 Apr; 64(4):781-9. PubMed ID: 26658683
[TBL] [Abstract][Full Text] [Related]
13. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
14. When can we stop nucleoside analogues in patients with chronic hepatitis B?
Chong CH; Lim SG
Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
[TBL] [Abstract][Full Text] [Related]
15. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
16. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.
Seto WK; Cheung KS; Wong DK; Huang FY; Fung J; Liu KS; Lai CL; Yuen MF
J Gastroenterol; 2016 May; 51(5):487-95. PubMed ID: 26446756
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
[TBL] [Abstract][Full Text] [Related]
19. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
[TBL] [Abstract][Full Text] [Related]
20. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
